| Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study U Banerji, CML van Herpen, C Saura, F Thistlethwaite, S Lord, V Moreno, ... The Lancet Oncology 20 (8), 1124-1135, 2019 | 416 | 2019 |
| Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression MA Dozynkiewicz, NB Jamieson, I MacPherson, J Grindlay, ... Developmental cell 22 (1), 131-145, 2012 | 357 | 2012 |
| Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial NC Turner, B Kingston, LS Kilburn, S Kernaghan, AM Wardley, ... The Lancet Oncology 21 (10), 1296-1308, 2020 | 231 | 2020 |
| Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry VG Brunton, IRJ MacPherson, MC Frame Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1692 (2-3), 121-144, 2004 | 229 | 2004 |
| Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others JMS Bartlett, J Bayani, A Marshall, JA Dunn, A Campbell, C Cunningham, ... JNCI: Journal of the National Cancer Institute 108 (9), djw050, 2016 | 214 | 2016 |
| N-WASP coordinates the delivery and F-actin–mediated capture of MT1-MMP at invasive pseudopods X Yu, T Zech, L McDonald, EG Gonzalez, A Li, I Macpherson, JP Schwarz, ... Journal of cell biology 199 (3), 527-544, 2012 | 190 | 2012 |
| Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors GD Demetri, P Lo Russo, IRJ MacPherson, D Wang, JA Morgan, ... Clinical Cancer Research 15 (19), 6232-6240, 2009 | 170 | 2009 |
| Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib A Serrels, IRJ Macpherson, TRJ Evans, FY Lee, EA Clark, OJ Sansom, ... Molecular cancer therapeutics 5 (12), 3014-3022, 2006 | 143 | 2006 |
| Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice H Cain, IR Macpherson, M Beresford, SE Pinder, J Pong, JM Dixon Clinical oncology 29 (10), 642-652, 2017 | 126 | 2017 |
| Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels D Novo, N Heath, L Mitchell, G Caligiuri, A MacFarlane, D Reijmer, ... Nature Communications 9 (1), 5069, 2018 | 106 | 2018 |
| CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer IR Macpherson, E Rainero, LE Mitchell, PVE van den Berghe, C Speirs, ... Journal of cell science 127 (18), 3893-3901, 2014 | 106 | 2014 |
| Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity JR Hernandez-Fernaud, E Ruengeler, A Casazza, LJ Neilson, E Pulleine, ... Nature communications 8 (1), 14206, 2017 | 101 | 2017 |
| Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells E Dornier, N Rabas, L Mitchell, D Novo, S Dhayade, S Marco, G Mackay, ... Nature communications 8 (1), 2255, 2017 | 81 | 2017 |
| p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism IR Macpherson, S Hooper, A Serrels, L McGarry, BW Ozanne, ... Oncogene 26 (36), 5214-5228, 2007 | 77 | 2007 |
| The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation L Rooshenas, LJ Scott, JM Blazeby, CA Rogers, KM Tilling, S Husbands, ... Journal of clinical epidemiology 106, 108-120, 2019 | 75 | 2019 |
| A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer. C Saura, F Thistlethwaite, U Banerji, S Lord, V Moreno, I MacPherson, ... Journal of Clinical Oncology 36 (15_suppl), 1014-1014, 2018 | 71 | 2018 |
| Genomic profile of advanced breast cancer in circulating tumour DNA B Kingston, RJ Cutts, H Bye, M Beaney, G Walsh-Crestani, S Hrebien, ... Nature communications 12 (1), 2423, 2021 | 67 | 2021 |
| Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial G Argilés, MP Saunders, F Rivera, A Sobrero, CG Ponce, S Cascinu, ... European journal of cancer 51 (8), 942-949, 2015 | 62 | 2015 |
| PINK1 drives production of mtDNA-containing extracellular vesicles to promote invasiveness N Rabas, S Palmer, L Mitchell, S Ismail, A Gohlke, JS Riley, SWG Tait, ... Journal of Cell Biology 220 (12), e202006049, 2021 | 57 | 2021 |
| The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: a qualitative systematic review and thematic synthesis N Peddie, S Agnew, M Crawford, D Dixon, I MacPherson, L Fleming The Breast 58, 147-159, 2021 | 57 | 2021 |
